Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
HarvardTrials will no longer be available as of June 7. You can search directly for Harvard-sponsored studies. If you have questions, please email us.
Check out the new look and feel of Harvard Catalyst Profiles! Learn more on our About and Help pages.

Christopher Paul Cannon, M.D.

Profile Picture

Phi Beta Kappa
Magna Cum Laude
NIH Students Research Fellowship Award
Aldred Steiner Research Award
NIH Student Research Fellowship Award
Alpha Omega Alpha
Robert F. Loeb Award for Excellence in Clinical Medicine
Upjohn Achievement in Research Award
2001 - 2001
Simon Dack Visiting Professor
2004 - 2004
Partners in Excellence Award
2005 - 2007
Best Doctors in America
2006 - 2007
Partners In Excellence Award
2007 - 2007
Best Doctors in Boston
Get With The Guidelines Special Recognition,
Leadership Award
Raymond Bahr Award of Excellence
2014 - 2016
Highly Cited Researchers; World’s Most Influential Scientific Minds

I am a cardiologist at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School. I also serve as Executive Director of Cardiometabolic Trials at the Baim Institute of Clinical Research. Over the past 27 years, I have been the principal investigator of more than 18 multicenter clinical trials including TACTICS-TIMI 18, PROVE IT-TIMI 22, IMPROVE IT and currently the RE-DUAL PCI trial.  My research has focused on management and prevention of acute coronary syndromes (ACS) with a goal of trying to directly improve patient care. Collaborating with others, we have helped establish various antithrombotic and interventional strategies for ACS, as well as long-term lipid management approaches for prevention that are included in current international guidelines. More recently, I am also studying prevention approaches in diabetes and in atrial fibrillation. Finally, I help lead registries and quality improvement educational initiatives with an aim toward implementation of research advances in clinical practice.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, Budaj A, Hamm C, Guo J, Im K, Kuder JF, Braunwald E, Sabatine MS, O'Donoghue ML. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Apr 18. PMID: 29710336.
    View in: PubMed
  2. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018 Apr 13. PMID: 29668889.
    View in: PubMed
  3. Cavender MA, White WB, Liu Y, Massaro JM, Bergenstal RM, Mehta CR, Zannad F, Heller S, Cushman WC, Cannon CP. Total Cardiovascular Events Analysis of the EXAMINE Trial in Patients with Type 2 Diabetes and Recent Acute Coronary Syndrome. Clin Cardiol. 2018 Apr 13. PMID: 29652078.
    View in: PubMed
  4. de Boer IH, Bakris G, Cannon CP. Individualizing Blood Pressure Targets for People With Diabetes and Hypertension: Comparing the ADA and the ACC/AHA Recommendations. JAMA. 2018 Apr 03; 319(13):1319-1320. PMID: 29543954.
    View in: PubMed
  5. White WB, Heller SR, Cannon CP, Howitt H, Khunti K, Bergenstal RM. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial. Am J Med. 2018 Mar 23. PMID: 29581078.
    View in: PubMed
  6. Cavallari I, Cannon CP, Braunwald E, Goodrich EL, Im K, Lukas MA, O'Donoghue ML. Metabolic syndrome and the risk of adverse cardiovascular events after an acute coronary syndrome. Eur J Prev Cardiol. 2018 May; 25(8):830-838. PMID: 29537291.
    View in: PubMed
  7. Udell JA, Fonarow GC, Maddox TM, Cannon CP, Peacock WF, Laskey WK, Grau-Sepulveda MV, Smith EE, Hernandez AF, Peterson ED, Bhatt DL. Sustained Sex-based Treatment Differences in Acute Coronary Syndrome Care: Insights from the American Heart Association Get With the Guidelines Coronary Artery Disease Registry. Clin Cardiol. 2018 Mar 09. PMID: 29521450.
    View in: PubMed
  8. Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, Louie MJ, Koren A, Letierce A, Mandel J, Banach M. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018 Mar 08. PMID: 29526502.
    View in: PubMed
  9. Baum SJ, Cannon CP. PCSK9 inhibitor valuation: A science-based review of the two recent models. Clin Cardiol. 2018 Apr; 41(4):544-550. PMID: 29512936.
    View in: PubMed
  10. Ibrahim N, Gaggin HK, Turchin A, Patel HK, Song Y, Trebnick A, Doros G, Maya JF, Cannon CP, Januzzi JL. Heart Rate, Beta Blocker Use, and Outcomes of Heart Failure with Reduced Ejection Fraction. Eur Heart J Cardiovasc Pharmacother. 2018 Feb 27. PMID: 29490032.
    View in: PubMed
  11. Cannon CP, Lip GYH, Oldgren J. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med. 2018 02 01; 378(5):485-486. PMID: 29385366.
    View in: PubMed
  12. Storey RF, Ardissino D, Vignali L, Cairns R, Becker RC, Cannon CP, Mahaffey KW, Himmelmann A, Katus HA, James SK, Wallentin L. Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO Study. Thromb Haemost. 2018 Feb; 118(2):427-429. PMID: 29443375.
    View in: PubMed
  13. Ibrahim NE, Song Y, Cannon CP, Doros G, Trebnick A, Russo P, Ponirakis A, Alexanian C, Januzzi JL. Addition or removal of guideline directed medical therapy in ambulatory patients with heart failure with reduced ejection fraction relative to change in symptom severity: An analysis from the PINNACLE (Practice Innovation and Clinical Excellence) Registry®. Int J Cardiol. 2018 03 01; 254:222-223. PMID: 29407094.
    View in: PubMed
  14. Garlo KG, White WB, Bakris GL, Zannad F, Wilson CA, Kupfer S, Vaduganathan M, Morrow DA, Cannon CP, Charytan DM. Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes. Clin J Am Soc Nephrol. 2018 Mar 07; 13(3):398-405. PMID: 29339356.
    View in: PubMed
  15. Cannon C, Khan I, Sanchez R. Simulation Models of Therapy Intensification in Lipid-Lowering Medicine-Reply. JAMA Cardiol. 2018 Jan 01; 3(1):89. PMID: 29188279.
    View in: PubMed
  16. Steen DL, Umez-Eronini AA, Guo J, Khan N, Cannon CP. The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: Insights from PROVE IT-TIMI 22. Clin Cardiol. 2018 Jan; 41(1):68-73. PMID: 29283450.
    View in: PubMed
  17. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10; 137(15):1571-1582. PMID: 29263150.
    View in: PubMed
  18. Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Levin A, Pollock C, Wheeler DC, Xie J, Zhang H, Zinman B, Desai M, Perkovic V. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. Am J Nephrol. 2017 Dec 13; 46(6):462-472. PMID: 29253846.
    View in: PubMed
  19. Hwang YC, Morrow DA, Cannon CP, Liu Y, Bergenstal R, Heller S, Mehta C, Cushman W, Bakris GL, Zannad F, White WB. High-sensitivity C-reactive protein, low-density lipoprotein cholesterol and cardiovascular outcomes in patients with type 2 diabetes in the EXAMINE (Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care) trial. Diabetes Obes Metab. 2018 Mar; 20(3):654-659. PMID: 29064626.
    View in: PubMed
  20. Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RP. Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). J Am Heart Assoc. 2017 Nov 18; 6(11). PMID: 29151034.
    View in: PubMed
  21. Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R. Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry. J Am Coll Cardiol. 2018 Jan 23; 71(3):292-302. PMID: 29141201.
    View in: PubMed